Shintaro Akiyama
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (20)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Colorectal cancer (CRC) is a leading cause of cancer‐related mortality, highlighting the need for early detection and accurate lesion characterization. Traditional white‐light imaging has limitations in detecting lesions, particularly those with flat morphology or minimal color contrast with the surrounding mucosa. It also struggles to distinguish neoplastic from non‐neoplastic lesions. These limitations led to the development of image‐enhanced endoscopy (IEE). Image‐enhanced endoscopy modalities such as narrow‐band imaging, blue laser imaging, linked color imaging, and texture and color enhancement imaging enhance mucosal surface and vascular pattern visualization, thereby improving lesion detection and characterization. In contrast, red dichromatic imaging is primarily designed to enhance the visibility of deep blood vessels, making it particularly useful during therapeutic endoscopies, such as identifying bleeding sources and monitoring post‐treatment hemostasis. Although IEE enhances lesion detection and characterization, it remains limited in assessing submucosal invasion depth, which is a key factor in treatment decisions. Endoscopic submucosal dissection requires accurate prediction of invasion depth; however, IEE mainly reflects superficial features. Endoscopic ultrasound and artificial intelligence‐assisted diagnostics have emerged as complementary techniques for improving depth assessment and lesion classification. Additionally, IEE plays a critical role in detecting ulcerative colitis‐associated neoplasia (UCAN), which often presents with a flat morphology and indistinct borders. High‐definition chromoendoscopy and IEE modalities enhance detection; however, inflammation‐related changes limit diagnostic accuracy. Artificial intelligence and molecular biomarkers may improve UCAN diagnosis. This review examines the role of IEE in lesion detection and treatment selection, its limitations, and complementary techniques such as endoscopic ultrasound and artificial intelligence. We also explored pit pattern diagnosis using crystal violet staining and discussed emerging strategies to refine colorectal cancer screening and management.
Year:
2026
Background The first‐choice treatment for immune checkpoint inhibitor (ICI)‐induced colitis is steroids; however, side effects may occur and survival may be reduced. Sulfasalazine (SSZ) is primarily used for inflammatory bowel disease but studies on ICI‐induced colitis are scarce. This study examined the efficacy and safety of SSZ for ICI‐induced colitis while testing SSZ as a steroid‐sparing agent. Methods This study (iRECSA) was a single‐arm, multicenter exploratory study from November 2021 to December 2024 that evaluated the efficacy and safety of SSZ for mild‐to‐moderate ICI‐induced colitis. SSZ was given at 4 g/day orally for 2 weeks. The primary outcome was clinical response (a ≥ 1‐point reduction from baseline partial Mayo score or partial Mayo score < 1). Secondary endpoints included clinical responses in the Simple Clinical Colitis Activity Index (SCCAI), Lichtiger Index, and Common Terminology Criteria for Adverse Events (CTCAE) grade, plus SSZ‐related adverse event incidence. Results Ten patients were enrolled. The median partial Mayo score decreased from 4 (range 3–5) to 2 (range 0–4), with 80% of patients achieving a clinical response. Similar response rates were observed with the Lichtiger Index and CTCAE grade. Defecation urgency was present in 70% of patients at baseline but resolved in all after treatment. Nine adverse events occurred in six patients; three patients discontinued SSZ because of hypersensitivity‐related adverse events. Three patients required systemic steroids after the study treatment. Conclusions This exploratory study suggests that SSZ may be a useful option for mild‐to‐moderate ICI‐induced colitis, but caution is warranted against SSZ‐related hypersensitivity.
Year:
2026
Aims We previously reported that telomerase activator Centella asiatica (CA) can normalize the crypt structure of human colonic organoids in an ulcerative colitis (UC) model. Therefore, we aimed to evaluate the safety and efficacy of CA for UC in a clinical trial. Methods and Results Ten patients with mild UC were recruited. Patients received 500 mg of oral CA extract tablets once daily for 12 weeks. Safety and efficacy were monitored based on clinical manifestations, biomarkers, endoscopic findings, histopathological findings, and telomere length. Among 10 patients, one patient withdrew due to the relapse of UC. No adverse events were identified during the medication in the remaining nine patients. One patient showed a Partial Mayo Score (pMayo) decrease from 1 to 0, while the remaining eight pMayo scores remained at 0 before and after treatment. CRP, ESR, and leucine‐rich alpha 2 glycoprotein (LRG) levels remained unchanged throughout treatment. Two patients showed endoscopic improvement. The other two patients showed histological improvement. Among five patients, relative telomere length of the rectum remained unchanged by treatment. Conclusion CA is safe for patients with UC. Longer treatment durations and larger participant pools are required to assess CA efficacy on histological healing in the future.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (9)
Toshimitsu Fujii
Tokyo Institute of Technology
mariko kobayashi
University of Tsukuba
Suguru Nishijima
Project Associate Professor
The Univeristy of Tokyo
Hideo Suzuki
Associate Professor
University of Tsukuba
Yasuhisa Sakata
Professor
Saga University
Bryan Mathis
Associate Professor
University of Tsukuba
David Rubin
Professor
University of Chicago
Katsuyoshi Matsuoka
Professor
-
Yuya Kondo
Lecturer
University of Tsukuba
Make your next move.
Prepare your application
Review drafts before you send them.